W
WAVEMAN · COMPANY
ONCO · Onconetix, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ONCO

Onconetix, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001782107
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$8.4K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
5
13F, latest reported quarter
REVENUE GROWTH
-67.7%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$8.4K over 180 days
+$8.4K of it by a 10%+ holder
more than 67% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
5 funds added or opened last quarter
below 96% of Pharma & Biotech
REVENUE
-67.7% year over year
below 88% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
5.0% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
more than 54% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -99.5%
-99.5%12M
-100%-53%-6%+41%2025-092025-102025-122026-032026-052026-072026-09 2026-04-20 · HRT FINANCIAL LP sold $70.8K2026-04-15 · HRT FINANCIAL LP bought $70.3K2026-04-14 · HRT FINANCIAL LP bought $57.2K2026-04-16 · HRT FINANCIAL LP sold $39.3K2026-04-21 · HRT FINANCIAL LP sold $34.3K2026-04-17 · HRT FINANCIAL LP bought $25.3K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $8.4K bought by insiders over 180 days, 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Onconetix, Inc. insiders bought a net $8.4K of stock across 6 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
HRT FINANCIAL LP
SELL
2026-04-21
49,710.0
$34.3K
HRT FINANCIAL LP
SELL
2026-04-20
94,462.0
$70.8K
HRT FINANCIAL LP
BUY
2026-04-17
34,636.0
$25.3K
HRT FINANCIAL LP
SELL
2026-04-16
53,867.0
$39.3K
HRT FINANCIAL LP
BUY
2026-04-15
92,554.0
$70.3K
6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
XTX Topco Ltd
13,548.0 sh
$15.3K
SBI Securities Co., Ltd.
252.0 sh
$285
Tower Research Capital LLC (TRC)
145.0 sh
$164
HOLLENCREST CAPITAL MANAGEMENT
100.0 sh
$113
HRT FINANCIAL LP
51,398.0 sh
$58
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$7.8K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$815.4K$2.5M$58.5K
GROSS PROFIT$632.9K$1.1M$-1.1M
OPERATING INCOME$-17.9M$-56.5M$-36.0M$-13.5M
NET INCOME$-14.0M$-58.7M$-37.4M$-13.4M
EPS (DILUTED)-16.56-1,823.39-87.45-1.10
OPERATING CASH FLOW$-9.7M$-10.5M$-13.6M$-8.7M
CASH$25.8M
BUYBACKS$566.8K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →